146 related articles for article (PubMed ID: 22048151)
1. Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points.
Kay A; Higgins J; Day AG; Meyer RM; Booth CM
Ann Oncol; 2012 Jun; 23(6):1646-51. PubMed ID: 22048151
[TBL] [Abstract][Full Text] [Related]
2. Evolution of the randomized controlled trial in oncology over three decades.
Booth CM; Cescon DW; Wang L; Tannock IF; Krzyzanowska MK
J Clin Oncol; 2008 Nov; 26(33):5458-64. PubMed ID: 18955452
[TBL] [Abstract][Full Text] [Related]
3. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.
Del Paggio JC; Berry JS; Hopman WM; Eisenhauer EA; Prasad V; Gyawali B; Booth CM
JAMA Oncol; 2021 May; 7(5):728-734. PubMed ID: 33764385
[TBL] [Abstract][Full Text] [Related]
4. Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?
Del Paggio JC; Azariah B; Sullivan R; Hopman WM; James FV; Roshni S; Tannock IF; Booth CM
Ann Oncol; 2017 Jan; 28(1):157-162. PubMed ID: 27742650
[TBL] [Abstract][Full Text] [Related]
5. Industry Funding of Oncology Randomised Controlled Trials: Implications for Design, Results and Interpretation.
Fundytus A; Wells JC; Sharma S; Hopman WM; Del Paggio JC; Gyawali B; Mukherji D; Hammad N; Pramesh CS; Aggarwal A; Sullivan R; Booth CM
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):28-35. PubMed ID: 34479769
[TBL] [Abstract][Full Text] [Related]
6. Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer.
Gan HK; You B; Pond GR; Chen EX
J Natl Cancer Inst; 2012 Apr; 104(8):590-8. PubMed ID: 22491345
[TBL] [Abstract][Full Text] [Related]
7. An Audit of Interim Analyses of Randomized Controlled Trials (RCTs) Published in Three High Impact Factor Medical Journals Over a Seven- year Period (2012-2018).
Bose D; Ravi R; Gogtay N; Thatte UM; Borse T
Rev Recent Clin Trials; 2021; 16(4):403-408. PubMed ID: 34259150
[TBL] [Abstract][Full Text] [Related]
8. Differences in Funding Sources of Phase III Oncology Clinical Trials by Treatment Modality and Cancer Type.
Jairam V; Yu JB; Aneja S; Wilson LD; Lloyd S
Am J Clin Oncol; 2017 Jun; 40(3):312-317. PubMed ID: 25374144
[TBL] [Abstract][Full Text] [Related]
9. Financial conflicts of interest and their association with outcome and quality of fibromyalgia drug therapy randomized controlled trials.
Pang WK; Yeter KC; Torralba KD; Spencer HJ; Khan NA
Int J Rheum Dis; 2015 Jul; 18(6):606-15. PubMed ID: 26012523
[TBL] [Abstract][Full Text] [Related]
10. The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.
Barton S; Peckitt C; Sclafani F; Cunningham D; Chau I
Eur J Cancer; 2015 Dec; 51(18):2732-9. PubMed ID: 26608121
[TBL] [Abstract][Full Text] [Related]
11. Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies.
Srikanthan A; Vera-Badillo F; Ethier J; Goldstein R; Templeton AJ; Ocana A; Seruga B; Amir E
Cancer Treat Rev; 2016 Feb; 43():67-73. PubMed ID: 26827694
[TBL] [Abstract][Full Text] [Related]
12. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments.
Roseman M; Milette K; Bero LA; Coyne JC; Lexchin J; Turner EH; Thombs BD
JAMA; 2011 Mar; 305(10):1008-17. PubMed ID: 21386079
[TBL] [Abstract][Full Text] [Related]
13. Characteristic Analysis of Complementary and Alternative Medicine in Randomized Controlled Trials of Oncology: A Comparison of Published Studies.
Zhang H; Yang G; Zhang W; Gu W; Su Y; Ling C
Integr Cancer Ther; 2018 Jun; 17(2):551-557. PubMed ID: 28627237
[TBL] [Abstract][Full Text] [Related]
14. Does Cancer Literature Reflect Multidisciplinary Practice? A Systematic Review of Oncology Studies in the Medical Literature Over a 20-Year Period.
Holliday EB; Ahmed AA; Yoo SK; Jagsi R; Hoffman KE
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):721-31. PubMed ID: 26104927
[TBL] [Abstract][Full Text] [Related]
15. Publication status of contemporary oncology randomised controlled trials worldwide.
Chen YP; Liu X; Lv JW; Li WF; Zhang Y; Guo Y; Lin AH; Sun Y; Mao YP; Ma J
Eur J Cancer; 2016 Oct; 66():17-25. PubMed ID: 27522246
[TBL] [Abstract][Full Text] [Related]
16. Survival end point reporting in randomized cancer clinical trials: a review of major journals.
Mathoulin-Pelissier S; Gourgou-Bourgade S; Bonnetain F; Kramar A
J Clin Oncol; 2008 Aug; 26(22):3721-6. PubMed ID: 18669458
[TBL] [Abstract][Full Text] [Related]
17. Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials.
Sharma S; Wells JC; Hopman WM; Del Paggio JC; Gyawali B; Hammad N; Hay AE; Booth CM
Curr Oncol; 2021 Apr; 28(2):1518-1527. PubMed ID: 33924380
[TBL] [Abstract][Full Text] [Related]
18. Trends in worldwide volume and methodological quality of surgical randomized controlled trials.
Ahmed Ali U; van der Sluis PC; Issa Y; Habaga IA; Gooszen HG; Flum DR; Algra A; Besselink MG
Ann Surg; 2013 Aug; 258(2):199-207. PubMed ID: 23774315
[TBL] [Abstract][Full Text] [Related]
19. Self-declared stock ownership and association with positive trial outcome in randomized controlled trials with binary outcomes published in general medical journals: a cross-sectional study.
Falk Delgado A; Falk Delgado A
Trials; 2017 Jul; 18(1):354. PubMed ID: 28747226
[TBL] [Abstract][Full Text] [Related]
20. Trends in the use and role of biomarkers in phase I oncology trials.
Goulart BH; Clark JW; Pien HH; Roberts TG; Finkelstein SN; Chabner BA
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6719-26. PubMed ID: 18006773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
